Effect of Novartis Access on availability and price of non-communicable disease medicines in Kenya: a cluster-randomised controlled trial

• Hoofdauteurs: Peter C Rockers, ScD (Auteur), Richard O Laing, ProfMD (Auteur), Paul G Ashigbie, DrPH (Auteur), Monica A Onyango, PhD (Auteur), Carol K Mukiira, MA (Auteur), Veronika J Wirtz, PhD (Auteur)
• Formaat: Boek
• Gepubliceerd in: Elsevier, 2019-04-01T00:00:00Z.
• Onderwerpen: article
• Online toegang: Connect to this object online.

Summary: Background: Novartis Access is a Novartis programme that offers a portfolio of non-communicable disease medicines at a wholesale price of US$1 per treatment per month in low-income and middle-income countries. We evaluated the effect of Novartis Access in Kenya, the first country to receive...